UC San Diego study links teenage cannabis initiation to slower gains in memory and thinking skills
A large longitudinal analysis of more than 11,000 U.S. youth in the Adolescent Brain Cognitive Development Study found that teens who began using cannabis showed restricted improvement over time in memory, attention, language, and processing speed compared with non-users. THC exposure was specifically associated with worse episodic memory trajectories. The findings, published in Neuropsychopharmacology, come from researchers at the University of California San Diego who combined self-reports with toxicological testing.
Key points
- •Teens initiating cannabis showed slower cognitive gains across multiple domains versus non-users in ABCD data.
- •Hair-detected THC linked to worse memory over time; CBD group showed no similar pattern.
- •Differences modest but potentially meaningful during rapid adolescent brain development; causality not proven.
Why this is uncovered
Covered by UC San Diego, ScienceDaily, local outlets, and medical trade press such as Medscape, with limited national mainstream pickup.
This article was generated automatically from primary sources and has not been reviewed by a human editor. Verify claims before sharing.
Researchers at the University of California San Diego School of Medicine have reported that teenagers who start using cannabis exhibit slower development of memory and thinking abilities than peers who do not use the substance. The analysis, published April 20, 2026, in Neuropsychopharmacology, drew on data from 11,036 participants in the Adolescent Brain Cognitive Development (ABCD) Study, the largest long-term investigation of brain development in U.S. youth (today.ucsd.edu).
Lead author Natasha Wade, PhD, assistant professor of psychiatry at UC San Diego, and colleagues followed children from ages 9–10 through ages 16–17. They tracked cognitive performance alongside substance use, combining self-reports with biological measures including hair, urine, and saliva samples to detect cannabis exposure over recent months to longer periods (today.ucsd.edu; nature.com).
Across domains that included immediate and delayed memory, processing speed, inhibitory control, visuospatial processing, language, and working memory, cannabis users showed altered trajectories with restricted growth relative to non-users (βs = −0.11 to −0.52). Some youths who later used cannabis performed as well as or slightly better than peers in late childhood, but their gains leveled off after initiation while non-users continued to improve (nature.com; sciencedaily.com).
In a secondary analysis of participants with repeated hair toxicology (n=645), evidence of delta-9-tetrahydrocannabinol (THC) exposure by age predicted worse episodic memory compared with controls (β = −0.60). No comparable difference appeared for those with cannabidiol (CBD) exposure versus controls, though the CBD group was small. Wade noted that the results point to THC as a likely driver and underscore the complexity of cannabis products, some of which labeled CBD may still contain THC (today.ucsd.edu; nature.com).
The observed differences were relatively modest. Researchers cautioned that the study does not establish direct causation; environmental factors, personality, or other variables could contribute. Analyses accounted for sociodemographics, family history of substance use disorder, prenatal exposures, early psychopathology, other substance use, and each participant’s prior cognitive performance, along with nesting for individual, site, and family effects (nature.com; sciencedaily.com).
“Adolescence is a critical time for brain development, and what we’re seeing is that teens who start using cannabis aren’t improving at the same rate as their peers,” Wade said. “These differences may seem small at first, but they can add up in ways that affect learning, memory and everyday functioning.” She added that delaying cannabis use supports healthy brain development as the substance becomes more widely available (today.ucsd.edu).
The team plans to continue following the cohort into young adulthood to examine longer-term effects, including the roles of timing and frequency of use. The work was supported in part by the National Institute on Drug Abuse and involved collaborators from UC San Diego, the University of Sydney, University of Wisconsin-Milwaukee, Columbia University, and others (today.ucsd.edu; nature.com).
Sources
- today.ucsd.eduhttps://today.ucsd.edu/story/largest-us-study-finds-teen-cannabis-use-linked-to-slower-cognitive-development
- nature.comhttps://www.nature.com/articles/s41386-026-02395-1
- sciencedaily.comhttps://www.sciencedaily.com/releases/2026/08/260806050726.htm
- news-medical.nethttps://www.news-medical.net/news/20260420/Teen-cannabis-use-linked-to-slower-growth-in-memory-and-thinking.aspx
- medscape.comhttps://www.medscape.com/viewarticle/teen-cannabis-use-tied-slower-cognitive-development-2026a1000e0h
- sandiegouniontribune.comhttps://www.sandiegouniontribune.com/2026/04/20/ucsd-marijuana-study-affirms-drugs-negative-effect-on-youth/
Want to respond?
The Uncovered has no comment section by design — we don't host or moderate discussions. If you still want to read along or join in, you can do so over Nostr, an open protocol where your replies live on your own key instead of on our server. Install NostrComments for Chrome or Firefox and the discussion appears on top of this page. Works on desktop and on Firefox for Android.
Open source, no tracking, free.
More in Health
Scientists at Nagoya University have shown that complement protein C3 produced inside tumors, rather than circulating in the blood, improves the effectiveness of immune checkpoint blockade therapy by limiting immunosuppressive myeloid cells. The findings, published in Nature Communications, were supported by mouse experiments and analysis of human lung cancer samples. Mimicking this local C3 effect restored treatment sensitivity in previously resistant tumors in mice.
9 Aug 2026
An observational study of over 17,000 UK Biobank participants found that meeting the standard 150 minutes per week of moderate-to-vigorous physical activity was associated with only an 8-9% lower risk of cardiovascular events. Achieving a greater than 30% risk reduction required roughly 560 to 610 minutes weekly, or three to four times current guidelines, with lower-fitness individuals needing slightly more activity for equivalent benefits. Researchers suggest future guidelines could distinguish minimum protection from optimal levels and personalize targets by fitness.
9 Aug 2026
A randomised controlled trial of nearly 4,000 New Zealand infants found no significant difference in rates of eczema or bronchiolitis between those given acetaminophen (paracetamol) and those given ibuprofen for fever or pain in the first year of life. Serious adverse events were rare and unrelated to either medication. The results, published in The Lancet Child & Adolescent Health, form the first-year findings of the ongoing PIPPA Tamariki study.
7 Aug 2026